Peptide Dendrimer−Liposome Nanocomplexes Advance mRNA Delivery Efficiency

Study Background and Research Question

Efficient delivery of nucleic acids, particularly mRNA, remains a critical challenge in gene therapy and vaccine development. While mRNA therapeutics offer high specificity and the potential for rapid protein expression, their clinical application is hindered by poor stability, susceptibility to degradation, and limited cellular uptake. Conventional delivery vehicles—such as lipid nanoparticles and cationic polymers—have achieved some success, but issues of immunogenicity, transfection efficiency, and biosafety persist. Advances in peptide-based carriers, especially peptide dendrimers with their unique branched architectures, have opened new possibilities for tailoring nucleic acid delivery systems. The reference study set out to address these bottlenecks by designing and characterizing peptide dendrimer−liposome nanocomplexes optimized for mRNA delivery.

Key Innovation from the Reference Study

The central innovation of the study lies in the development of hybrid nanocomplexes composed of peptide dendrimers (KEL-G1 and KEL-G2) and cationic liposomes (DOTAP). These peptide dendrimer−liposome complexes—termed KEL-G@DOTAP—exhibit uniform nanoscale sizes (approximately 100−250 nm) and a positive surface charge. This rational design leverages the multibranched, highly functionalized surface of peptide dendrimers, which enhances nucleic acid binding and cellular membrane interactions, while the liposomal component augments stability and facilitates endosomal escape. Unlike previous approaches that focused primarily on siRNA, this work provides a robust platform specifically adapted for the more challenging task of mRNA delivery, offering improved transfection efficiency and biosafety.

Methods and Experimental Design Insights

The study synthesized two generations of lysine/glutamic acid-based peptide dendrimers (KEL-G1 and KEL-G2) via standard solid-phase peptide synthesis. These dendrimers were then complexed with the cationic liposome DOTAP to form nanocomplexes under controlled conditions, optimizing parameters such as dendrimer:liposome ratio and total nucleic acid payload. Physicochemical properties—including particle size, zeta potential, and morphology—were characterized using dynamic light scattering and electron microscopy, confirming the formation of monodisperse nanoparticles with favorable uptake characteristics.

To assess delivery efficiency, both mRNA and siRNA were loaded into the nanocomplexes and introduced into mammalian cell lines. Protein expression from delivered mRNA was quantified, and gene silencing was evaluated for siRNA. In vivo experiments involved delivering mRNA-encoded reporter genes to mouse lungs, with subsequent analysis of protein expression to evaluate tissue targeting and translation efficiency. Biosafety was also assessed through cytotoxicity assays and in vivo biocompatibility studies.

Core Findings and Why They Matter

The KEL-G@DOTAP nanocomplexes demonstrated several key advantages over conventional transfection reagents:

• Enhanced Cellular Uptake: The uniform nanoscale size and positive surface charge of the complexes facilitated rapid and efficient internalization by target cells (reference study).
• Superior Transfection Efficiency: For both mRNA and siRNA, the peptide dendrimer−liposome system achieved up to 7–10-fold higher gene expression and gene silencing compared to the widely-used Lipo2000 reagent in certain cell types.
• Targeted In Vivo Delivery: The KEL-G2/DOTAP/KE formulation enabled targeted mRNA delivery to mouse lung tissue, resulting in high levels of protein expression, demonstrating tissue-specific delivery capacity.
• Improved Biosafety: Cytotoxicity and in vivo biocompatibility assays confirmed that the nanocomplexes exhibited low toxicity and good safety profiles, an essential feature for therapeutic translation.

These findings significantly advance the field of mRNA delivery. The ability to efficiently deliver and translate mRNA in vivo while maintaining biosafety addresses core limitations that have slowed the adoption of mRNA-based therapeutics and gene editing approaches.

Comparison with Existing Internal Articles

Recent internal articles provide complementary perspectives on the challenges and solutions in mRNA delivery and transfection. For instance, the article "EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Cap1, 5-mo..." highlights the role of 5-moUTP-modified, Cap1-capped, and Cy5-labeled mRNA reporters in enhancing stability and suppressing innate immune activation. These features enable more reliable translation efficiency assays and precise imaging, which are key for evaluating the performance of new delivery systems like KEL-G@DOTAP.

Similarly, "EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Reporter for Advanced mRNA Delivery" discusses how dual-labeled mRNAs empower researchers to simultaneously track delivery and quantify translation, streamlining the optimization of delivery platforms. The integration of such advanced reporter constructs—featuring innate immune activation suppression and dual-mode detection—provides practical tools for benchmarking the efficacy and safety of novel nanocomplexes as developed in the reference study.

These internal resources collectively support the notion that advances in both mRNA chemistry and delivery vehicle engineering are synergistic, with each domain reinforcing progress in the other.

Limitations and Transferability

While the KEL-G@DOTAP peptide dendrimer−liposome system exhibits clear advantages, some limitations should be noted:

• Cell Type Specificity: The magnitude of transfection efficiency gains varied across different cell lines, indicating that optimization may be necessary for specific applications or tissue targets.
• In Vivo Translation: Although promising results were obtained for lung-targeted delivery, broader biodistribution and repeat-dosing studies are needed to fully characterize safety and efficacy profiles.
• Scalability and Manufacturing: The synthesis of peptide dendrimers and their assembly into uniform nanocomplexes at scale remains a practical consideration for translational and clinical applications.

Nevertheless, the design principles demonstrated here—such as modular assembly, charge engineering, and amphiphilicity—offer a flexible framework for adapting these systems to diverse nucleic acid cargos and therapeutic contexts.

Protocol Parameters

• Dendrimer synthesis: Solid-phase peptide synthesis; optimize generation number (G1 vs. G2) for desired branching and surface functionality.
• Nanocomplex assembly: Typical dendrimer:liposome:RNA mass ratios can range from 1:2:1 to 2:2:1; empirically determine for each mRNA cargo.
• Particle size targeting: Aim for 100−250 nm hydrodynamic diameter to maximize cellular uptake and minimize rapid clearance.
• Surface charge: Positive zeta potential improves membrane interaction but may require tuning to balance cytotoxicity and uptake.
• Transfection incubation: 4–24 hours in culture; monitor for peak protein expression and minimal cytotoxicity.
• In vivo dosing: Intratracheal or systemic administration in murine models; adjust mRNA dose based on tissue target and reporter sensitivity.

Research Support Resources

To facilitate benchmarking and optimization of mRNA delivery and translation efficiency, researchers can employ advanced dual-reporter mRNA constructs. EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010) integrates Cap1 capping, 5-moUTP modification, and Cy5 labeling for enhanced stability, reduced immunogenicity, and dual-mode detection. This reagent is suitable for testing new delivery vehicles, quantifying translation efficiency, and supporting in vivo bioluminescence imaging or fluorescence-based trafficking assays, as explored in both the reference study and related internal literature. APExBIO provides detailed protocol guidance and quality controls for this product, making it a practical resource for researchers investigating next-generation mRNA delivery systems.